通过调节脂质代谢,PLIN1可以抑制质瘤的进展
Kui Luo1, Kai Zhuang1, Hao Wu1
1Department of Neurosurgery, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
Cell death & disease
|January 27, 2025
概括
利1 (PLIN1) 在质瘤中下调,预后恶化. 恢复PLIN1可以抑制质瘤的生长和侵袭,并通过PI3K/AKT通路重新编程脂质代谢.
科学领域:
- 神经瘤学神经瘤学
- 癌症生物学 癌症生物学
- 分子医学是分子医学.
背景情况:
- 质瘤是一种高度异质和破坏性的脑瘤,预后不佳.
- 识别早期诊断和预后标志物对于改善质瘤治疗结果至关重要.
研究的目的:
- 为了研究Perilipin 1 (PLIN1) 在质瘤中的作用.
- 探索潜在的分子机制,包括它与PI3K/AKT信号通路的关系.
主要方法:
- 在33个质瘤和15个正常大脑样本上进行RNA下一代测序.
- 细胞实验评估PLIN1调控对质瘤细胞生长,侵入和脂质代谢的影响.
- 研究PI3K/AKT通路对PLIN1表达的影响.
主要成果:
- 发现利1 (PLIN1) 在质瘤组织中降低调节,并与患者的治疗结果较差相关.
- PLIN1的升级显著抑制了质瘤细胞的增殖和侵入.
- 过度表达PLIN1通过调高脂质生物合成和调低脂解基因来促进脂质积累.
- PI3K/AKT轴被确定为PLIN1水平的调节者,其抑制增加了PLIN1的表达.
结论:
- PI3K/AKT轴的调节失调导致质瘤中Perilipin 1 (PLIN1) 的下调.
- 降低PLIN1的调节有助于质瘤的扩散,侵袭和改变脂质代谢.
- PLIN1代表了质瘤治疗的潜在治疗点.
更多相关视频
12:52Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
Published on: November 28, 2015
15.7K
10:13Modeling Astrocytoma Pathogenesis In Vitro and In Vivo Using Cortical Astrocytes or Neural Stem Cells from Conditional, Genetically Engineered Mice
Published on: August 12, 2014
13.4K
相关概念视频
Abnormal Proliferation
4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
Interactions Between Signaling Pathways
6.2K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.2K
PI3K/mTOR/AKT Signaling Pathway
3.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.4K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
